Clinical year in review II: Interstitial lung disease, sepsis, pulmonary infections, and sleep medicine

Proceedings of the American Thoracic Society

Volumn 4, Issue 6, 2007, Pages 482-488

  Moss, Marc ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AZATHIOPRINE; BOSENTAN; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN; INFLIXIMAB; LEVOFLOXACIN; MACROLIDE; MEROPENEM; METYRAPONE; PIRFENIDONE; PLACEBO; PREDNISONE; TELOMERASE REVERSE TRANSCRIPTASE; TETRACOSACTIDE; VANCOMYCIN;

ADRENAL INSUFFICIENCY; ANTIBIOTIC RESISTANCE; ATHEROSCLEROSIS; BRONCHIOLITIS; BRONCHOSCOPY; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; DIAGNOSTIC PROCEDURE; DRIVING ABILITY; DRUG EFFICACY; DRUG WITHDRAWAL; FAMILIAL DISEASE; FIBROSING ALVEOLITIS; GENE EXPRESSION; GENETIC DIFFERENCE; GENETIC TRANSCRIPTION; HUMAN; HYPOXIA; INTERSTITIAL LUNG DISEASE; LUNG INFECTION; META ANALYSIS; MONOTHERAPY; MORBIDITY; NONHUMAN; POLYSOMNOGRAPHY; POSITIVE END EXPIRATORY PRESSURE; RANDOMIZED CONTROLLED TRIAL; SARCOIDOSIS; SCLERODERMA; SCORING SYSTEM; SEPSIS; SLEEP APNEA SYNDROME; SYSTEMATIC REVIEW; VENTILATOR ASSOCIATED PNEUMONIA;

HUMANS; LUNG DISEASES, INTERSTITIAL; MORBIDITY; PNEUMONIA, BACTERIAL; PULMONARY DISEASE (SPECIALTY); SEPSIS; SLEEP APNEA SYNDROMES; UNITED STATES;

EID: 35148842912     PISSN: 15463222     EISSN: None     Source Type: Journal    
DOI: 10.1513/pats.200707-089TT     Document Type: Conference Paper

References (37)

1. Newman LS, Rose CS, Maier LA. Sarcoidosis. N Engl J Med 1997;336:1224-1234.
2. Doty JD, Mazur JE, Judson MA. Treatment of sarcoidosis with infliximab. Chest 2005;127:1064-1071.
3. Baughman RP, Drent M, Kavuru M, Judson MA, Costabel U, du Bois R, Albera C, Brutsche M, Davis G, Donohue JF, et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 2006;174:795-802.
4. Steen VD, Conte C, Owens GR, Medsger TA Jr. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 1994;37:1283-1289.
5. Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, Arriola E, Silver R, Strange C, Bolster M, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006;354:2655-2666.
6. Hoyles RK, Ellis RW, Wellsbury J, Lees B, Newlands P, Goh NS, Roberts C, Desai S, Herrick AL, McHugh NJ, et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 2006;54:3962-3970.
7. Portnoy J, Veraldi KL, Schwarz MI, Cool CD, Curran-Everett D, Cherniack RM, King TE Jr, Brown KK. Respiratory bronchiolitis-interstitial lung disease: long-term outcome. Chest 2007;131:664-671.
8. Harley CB, Futcher AB, Greider CW. Telomeres shorten during ageing of human fibroblasts. Nature 1990;345:458-460.
9. Armanios MY, Chen JJ, Cogan JD, Alder JK, Ingersoll RG, Markin C, Lawson WE, Xie M, Vulto I, Phillips JA III, et al. Telomerase mutations in families with idiopathic pulmonary fibrosis. N Engl J Med 2007;356:1317-1326.
10. Tsakiri KD, Cronkhite JT, Kuan PJ, Xing C, Raghu G, Weissler JC, Rosenblatt RL, Shay JW, Garcia CK. Adult-onset pulmonary fibrosis caused by mutations in telomerase. Proc Natl Acad Sci USA 2007;104:7552-7557.
11. Hodgson U, Pulkkinen V, Dixon M, Peyrard-Janvid M, Rehn M, Lahermo P, Ollikainen V, Salmenkivi K, Kinnula V, Kere J, et al. ELMOD2 is a candidate gene for familial idiopathic pulmonary fibrosis. Am J Hum Genet 2006;79:149-154.
12. Yang IV, Burch LH, Steele MP, Savov JD, Hollingsworth JW, Elvania-Tekippe E, Berman KG, Speer MC, Sporn TA, Brown KK, et al. Gene expression profiling of familial and sporadic interstitial pneumonia. Am J Respir Crit Care Med 2007;175:45-54.
13. Martin GS, Mannino DM, Moss M. The effect of age on the development and outcome of adult sepsis. Crit Care Med 2006;34:15-21.
14. Danai PA, Moss M, Mannino DM, Martin GS. The epidemiology of sepsis in patients with malignancy. Chest 2006;129:1432-1440.
15. Moss M, Burnham EL. Alcohol abuse in the critically ill patient. Lancet 2006;368:2231-2242.
16. O'Brien JM Jr, Lu B, Ali NA, Martin GS, Aberegg SK, Marsh CB, Lemeshow S, Douglas IS. Alcohol dependence is independently associated with sepsis, septic shock, and hospital mortality among adult intensive care unit patients. Crit Care Med 2007;35:345-350.
17. Annane D, Sebille V, Charpentier C, Bollaert PE, Francois B, Korach JM, Capellier G, Cohen Y, Azoulay E, Troche G, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002;288:862-871.
18. Hamrahian AH, Oseni TS, Arafah BM. Measurements of serum free cortisol in critically ill patients. N Engl J Med 2004;350:1629-1638.
19. Annane D, Maxime V, Ibrahim F, Alvarez JC, Abe E, Boudou P. Diagnosis of adrenal insufficiency in severe sepsis and septic shock. Am J Respir Crit Care Med 2006;174:1319-1326.
20. Hackam DG, Mamdani M, Li P, Redelmeier DA. Statins and sepsis in patients with cardiovascular disease: a population-based cohort analysis. Lancet 2006;367:413-418.
21. Gupta R, Plantinga LC, Fink NE, Melamed ML, Coresh J, Fox CS, Levin NW, Powe NR. Statin use and hospitalization for sepsis in patients with chronic kidney disease. JAMA 2007;297:1455-1464.
22. Turgeon AF, Hutton B, Fergusson DA, McIntyre L, Tinmouth AA, Cameron DW, Hebert PC. Meta-analysis: intravenous immunoglobulin in critically ill adult patients with sepsis. Ann Intern Med 2007;146:193-203.
23. Ziegler EJ, Fisher CJ Jr, Sprung CL, Straube RC, Sadoff JC, Foulke GE, Wortel CH, Fink MP, Dellinger RP, Teng NN. Treatment of gramnegative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin: a randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. N Engl J Med 1991;324:429-436.
24. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM Jr, Musher DM, Niederman MS, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44:S27-S72.
25. Dunbar LM, Wunderink RG, Habib MP, Smith LG, Tennenberg AM, Khashab MM, Wiesinger BA, Xiang JX, Zadeikis N, Kahn JB. Highdose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clin Infect Dis 2003;37:752-760.
26. el Moussaoui R, de Borgie CA, van den Broek P, Hustinx WN, Bresser P, van den Berk GE, Poley JW, van den Berg B, Krouwels FH, Bonten MJ, et al. Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised, double blind study. BMJ 2006;332:1355.
27. Fagon JY, Chastre J, Wolff M, Gervais C, Parer-Aubas S, Stephan F, Similowski T, Mercat A, Diehl JL, Sollet JP, et al. Invasive and noninvasive strategies for management of suspected ventilator-associated pneumonia: a randomized trial. Ann Intern Med 2000;132:621-630.
28. Ruiz M, Torres A, Ewig S, Marcos MA, Alcon A, Lledo R, Asenjo MA, Maldonaldo A. Noninvasive versus invasive microbial investigation in ventilator-associated pneumonia: evaluation of outcome. Am J Respir Crit Care Med 2000;162:119-125.
29. The Canadian Critical Care Trials Group. A randomized trial of diagnostic techniques for ventilator-associated pneumonia. N Engl J Med 2006;355:2619-2630.
30. Bouza E, Torres MV, Radice C, Cercenado E, de Diego R, Sanchez-Carrillo C, Munoz P. Direct E-test (AB Biodisk) of respiratory samples improves antimicrobial use in ventilator-associated pneumonia. Clin Infect Dis 2007;44:382-387.
31. Daneman N, McGeer A, Green K, Low DE. Macrolide resistance in bacteremic pneumococcal disease: implications for patient management. Clin Infect Dis 2006;43:432-438.
32. Marin JM, Carrizo SJ, Vicente E, Agusti AG. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet 2005;365:1046-1053.
33. Pack AI. Advances in sleep-disordered breathing. Am J Respir Crit Care Med 2006;173:7-15.
34. Savransky V, Nanayakkara A, Li J, Bevans S, Smith PL, Rodriguez A, Polotsky VY. Chronic intermittent hypoxia induces atherosclerosis. Am J Respir Crit Care Med 2007;175:1290-1297.
35. Mulgrew AT, Fox N, Ayas NT, Ryan CF. Diagnosis and initial management of obstructive sleep apnea without polysomnography: a randomized validation study. Ann Intern Med 2007;146:157-166.
36. Pack AI, Maislin G, Staley B, Pack FM, Rogers WC, George CF, Dinges DF. Impaired performance in commercial drivers: role of sleep apnea and short sleep duration. Am J Respir Crit Care Med 2006;174:446-454.
37. Puhan MA, Suarez A, Lo CC, Zahn A, Heitz M, Braendli O. Didgeridoo playing as alternative treatment for obstructive sleep apnoea syndrome: randomised controlled trial. BMJ 2006;332:266-270.